Evidence map›Paper›PMID 38087013›Full record

ArticleMedical oncology (Northwood, London, England)2023

What is the optimal (neo)adjuvant strategy of extremity high-risk soft tissue sarcomas (ESTS)?

Saoussane Kharmoum, Jinane Kharmoum, Mariam Chraibi, Sylvie Bonvalot, Jean-Yves Blay, Mohammed Shimi

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Saoussane KharmoumRegional Hospital Center, Tangier, Morocco. dr.saoussane.kharmoum@gmail.com.ORCID http://orcid.org/0000-0003-1551-3493
Jinane KharmoumLaboratory of Pathology, University Hospital Center Mohamed VI, Faculty of Medecine and Pharmacy Tangier, Abdelmalek Essadi University, Tétouan, Morocco.
Mariam ChraibiLaboratory of Pathology, University Hospital Center Mohamed VI, Faculty of Medecine and Pharmacy Tangier, Abdelmalek Essadi University, Tétouan, Morocco.
Sylvie BonvalotDepartment of Surgical Oncology, Sarcoma Unit, Institut Curie, Paris, France.
Jean-Yves BlayDepartement of Medical Oncology, Leon Berard Center, University CI. Bernard, Lyon, France.
Mohammed ShimiTrauma Orthopedic Departement, University Hospital Center Mohamed VI, Faculty of Medecine and Pharmacy Tangier, Abdelmalek Essadi University, Tétouan, Morocco.
Abdelmalek Essaâdi University · MACentre Léon Bérard · FRHôpital régional · CHInstitut Curie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the standard treatment for extremity high-risk soft tissue sarcomas (ESTS) combines surgery and pre- or post-op radiation therapy (RT). In some selected cases, chemotherapy (CT) is incorporated into the therapeutic algorithm as a neoadjuvant approach to enable conservative management. Given the risk of local or metastatic relapse, this paper discusses the potential benefits of CT and RT in high-grade ESTs. The role of adjuvant chemotherapy in addition to neoadjuvant CT, the prognostic value of the pathological response to neoadjuvant treatment, and the role for an adjuvant "boost" following resection after pre-operative radiotherapy will be discussed.

Indexed as

SarcomaSoft Tissue NeoplasmsAdjuvants, ImmunologicChemotherapy, AdjuvantExpressed Sequence TagsExtremitiesHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalRadiotherapy, AdjuvantAdjuvants, ImmunologicAdjuvant therapyBoost radiotherapyExtremity high risk soft tissue sarcomasNeoadjuvant strategyPathological response

Identifiers

PMID38087013
OpenAlexW4389612248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.